Virginia Commonwealth University Researcher Highlights Recent Research in Breast Cancer (BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer).

Předmět:	BREAST cancer research BREAST cancer SELECTIVE estrogen receptor modulators CYTOCHROME P-450 CYP3A ESTROGEN
Zdroj:	Women's Health Weekly; 8/29/2023, p1290-1290, 1p
Abstrakt:	The standard of care for ER+ breast cancer involves estrogen antagonists such as tamoxifen or fulvestrant in combination with CDK4/6 inhibitors such as palbociclib. Keywords: Antineoplastics; Breast Cancer; Cancer; Cytochrome P450 3A Inhibitors; DNA-Binding Proteins; Drugs and Therapies; Endocrinology; Estrogen; Estrogen Receptor Antagonists; Estrogen Receptors; Fulvestrant Therapy; Genetics; Health and Medicine; Hormones; Kinase Inhibitors; Oncology; Palbociclib Therapy; Pharmaceuticals; Proteins; Selective Estrogen Receptor Modulators; Steroid Receptors; Tamoxifen; Tamoxifen Therapy; Transcription Factors; Women's Health; p53 Gene EN Antineoplastics Breast Cancer Cancer Cytochrome P450 3A Inhibitors DNA-Binding Proteins Drugs and Therapies Endocrinology Estrogen Estrogen Receptor Antagonists Estrogen Receptors Fulvestrant Therapy Genetics Health and Medicine Hormones Kinase Inhibitors Oncology Palbociclib Therapy Pharmaceuticals Proteins Selective Estrogen Receptor Modulators Steroid Receptors Tamoxifen Tamoxifen Therapy Transcription Factors Women's Health p53 Gene 1290 1290 1 08/28/23 20230829 NES 230829 2023 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on breast cancer. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu